Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | TYMP | P19971 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11369850 | 0.87 | CA12 (0.51) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL11390072 | 0.84 | CA12 (0.64) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL15570076 | 0.83 | CA12 (0.56) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL11350180 | 0.81 | KMT2A (0.60) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL17029295 | 0.81 | LMNA (0.48) | CA12CA1CA2CA9KMT2A | |
| Hydrochloric Acid SCHEMBL11385514 | 0.80 | KMT2A (0.59) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL28629774 | 0.79 | CA12 (0.44) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL15570078 | 0.78 | CA12 (0.46) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL9806181 | 0.78 | CA12 (0.46) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL14199605 | 0.78 | CA12 (0.46) | CA12CA1CA2CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10357577-B2 | Bacterial nitroreductase enzymes and methods relating thereto | AUCKLAND UNISERVICES LIMITED (NZ) | 2019-07-23 | — | — | US | disclosed |
| US-9006237-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-14 | — | — | US | disclosed |
| US-9006237-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-14 | — | — | US | disclosed |
| US-9006237-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-14 | — | — | US | disclosed |
| US-20130295011-A1 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | VICTORIA LINK LIMITED (NZ) | 2013-11-07 | — | — | US | disclosed |
| EP-2593796-A2 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | Auckland Uniservices Limited (NZ) | 2013-05-22 | — | — | EP | disclosed |
| US-20120232075-A1 | Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases | ANDREWS MARTIN JAMES INGLIS (BE) | 2012-09-13 | — | — | US | disclosed |
| US-20120232075-A1 | Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases | ANDREWS MARTIN JAMES INGLIS (BE) | 2012-09-13 | — | — | US | disclosed |
| US-20120232075-A1 | Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases | ANDREWS MARTIN JAMES INGLIS (BE) | 2012-09-13 | — | — | US | disclosed |
| US-8148369-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-03 | — | — | US | disclosed |
| US-8148369-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-03 | — | — | US | disclosed |
| US-8148369-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-03 | — | — | US | disclosed |
| WO-2012008860-A2 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-01-19 | — | — | WO | disclosed |
| US-20090012078-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, N.V. (BE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012078-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, N.V. (BE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012078-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, N.V. (BE) | 2009-01-08 | — | — | US | disclosed |
| WO-2008138842-A1 | IMIDAZOPYRAZINES AND TRIAZOLOPYRAZINE FOR THE TREATMENT OF JOINT DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-11-20 | — | — | WO | disclosed |
| EP-1206937-B1 | NITROIMIDAZOLE EXTERNAL PREPARATIONS FOR THE TREATMENT OF ATOPIC DERMATITIS | SHOEI CO LTD (JP) | 2008-01-23 | — | — | EP | disclosed |
| US-20030092754-A1 | External preparation for skin diseases containing nitroimidazole | SHOEI CO., LTD. (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1206937-A1 | NITROIMIDAZOLE EXTERNAL PREPARATIONS FOR DERMATOSIS | SHOEI CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012078-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | TNF, LITAF, CNKSR1 | CA12 4832/4885CA1 4471/4885CA2 4857/4885 |
| US-20120232075-A1 | Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases | TNF, LITAF, CNKSR1 | CA12 4832/4885CA1 4471/4885CA2 4857/4885 |
| US-20030092754-A1 | External preparation for skin diseases containing nitroimidazole | IL4I1, NSD1, CUTA | CA12 4684/4885CA1 4838/4885CA2 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.